Founded in 1999, Dexcom, Inc. (NASDAQ: DXCM), develops and markets Continuous Glucose Monitoring (CGM) systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes. The company is the leader in transforming diabetes care and management by providing CGM technology to help patients and healthcare professionals better manage diabetes. Since the company's inception, Dexcom has focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class - while empowering the community to take control of diabetes. Dexcom reported full-year 2022 revenues of $2.9B, a growth of 18% over 2021. Headquartered in San Diego, California, with additional offices in the Americas, Europe, and Asia Pacific, the company employs over 8,000 people worldwide.
Meet the team:
As an influential member of Dexcom's Advanced Research & Technology organization, the Sr Biosensor Scientist will partake in proof-of-concept and feasibility initiatives focused on novel sensing concepts, leading to the development of the Company's next generation biosensor products. The ideal candidate comes equipped with a track record of innovative thinking within the biosensors and biomedical devices fields and demonstrated ability to work cross-functionally in a highly collaborative, fast-paced innovation environment. The individual is expected to have clear understanding of the technical challenges associated with medical device development and will be responsible for conceiving, developing, validating, and implementing technical solutions that meet business objectives. In this capacity, the Sr Scientist will have a key role in the creation and maintenance of performance targets, develop and reduce concepts to robust feasibility demonstrators, identify and mitigate risks, and collaborate with internal stakeholders to transition advanced research / Phase 0 programs to core product development initiatives.
Where you come in:
What makes you successful:
Travel Required: